Navigation Links
Starfish Heart Positioner

ProductsStarfish Heart Positioner
Company Medtronic Inc.
Item Starfish Heart Positioner
Features 
  • Facilitates access to and exposure of the cornonaries.
  • The multi-appendage, silicone suction cup provides attachment to the apex, and the left ventricle immediately lateral to the apex, to greatly enhance lateral wall exposure.
  • Description Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compared to DPS.
    Info Medtronic Inc.
    Customer Service: (800) 551-5544
    Web site: http://www.medtronic.com/

    Related medicine products :

    1. Starfish 2 Heart Positioner
    2. Starfish NS Heart Positioner
    3. CO2 R Heart Laser 2
    4. Heartstring™
    5. HeartSpeed HB Bi-plane Cardiac System
    6. HeartMate LVAS
    7. TandemHeart PTVA (Percutaneous Transseptal Ventricular Assist) System
    8. LionHeart Left Ventricular Assist System (LVAS)
    9. Urchin Heart Positioner
    10. Cambridge Heart CH2000 Stress-Test System
    11. Aescula LV Left-Heart Lead
    Used for complex diagnostic and interventional procedures....
    ... St. Jude Medical offers a ... for use with percutaneous catheter ... of intravascular catheters. Our diagnostic ... lengths and incorporate a proprietary ...
    ... VISION Coronary Stent System is Guidant's first ... stents. Cobalt chromium is stronger and more ... chromium stent can have similar strength and ... with struts that are only .0032" thick. ...
    ... The CYPHER Sirolimus-eluting Coronary ... antiproliferative drug, called "sirolimus", a ... stent delivery platform. Upon placement, ... wall and impedes the process ...
    Medicine Products:
    (Date:12/6/2009)... to avoid oysters harvested from San Antonio Bay ... U.S. Food and Drug Administration is advising consumers to ... on or after Nov. 16 due to reports of ... harvested from this area, which is located on the ... ) ,, The FDA, along with the Centers ...
    (Date:12/6/2009)... growth factor, researchers say , , SUNDAY, Dec. 6 ... from the main tumor to other parts of the ... TGFb, which may prove a promising target for new ... , Previous studies have shown that TGFb (transforming growth ... this new study, a team from Cancer Research UK ...
    (Date:12/6/2009)... -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Phase 2b 003-A1 study, known as the 003 ... pre-treated relapsed and refractory multiple myeloma patients. These ... Symposium at the 51st annual meeting of the ... Enrollment in this trial is complete (n=269), and ...
    (Date:12/6/2009)... A new study provides welcome news for patients with ... , The condition is estimated to impact 62,000 ... an abnormal clot forms in a vein and restricts ... some cases, the clot may detach from its point ... lungs, causing a potentially fatal condition known as a ...
    (Date:12/6/2009)... Attorney Joseph W. Belluck of Belluck & Fox, LLP says dangerous ... holiday seasons. , ... New York, NY (PRWEB) December ... holiday season, they should be alert to reports of recalls due ... injury lawyer., , ,“Close to 230,000 children visit hospital emergency rooms ...
    Breaking Medicine News(10 mins):Health News:FDA, CDC, and States Investigating Norovirus Illnesses Linked to Oysters 2Health News:Breast Cancer's Spread Now Better Understood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3
    ... healthcare real estate company providing ... hospitals and physicians ... CHARLOTTE, N.C., Jan. 23 Cogdell Spencer Inc.,(NYSE: ... agreement,to acquire 100 percent of the stock of Marshall Erdman ...
    ... [Brown University] When faced with even a ... fewer women receive these potentially life-saving breast cancer ... University and Harvard Medical School researchers. , In ... insurance co-payments and mammography rates, researchers found that ...
    ... 23 Pennsylvania,AFL-CIO President William George and Secretary ... decisions by,Representatives John Peterson, Joseph Pitts, and William ... millions of children in,families hit hardest by our ... in the face of a severe economic downturn,Representatives ...
    ... Jan. 23 Johnson & Johnson,Pharmaceutical Research & ... Drug Application (NDA) to the U.S. Food and ... an investigational oral analgesic for the relief of ... American Pain Foundation, more than 25 million,Americans experience ...
    ... Jan. 23 Boston Scientific (NYSE: BSX ),today ... Chief,Medical and Scientific Officer, on an article in the ... and Drug-Eluting Stents for,Off-Label Indications.", "The analysis from ... in today,s New England Journal of Medicine is the ...
    ... went five years without anti-rejection drugs , , WEDNESDAY, ... transplant recipients to stop taking powerful immunosuppressive drugs are ... in the development of the transplant field is to ... the lifesaving benefit of the transplant without the costs ...
    Other Medicine News:Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 2Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 3Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 4Health News:Cogdell Spencer Inc. Announces Merger with Marshall Erdman and Associates 5Health News:Health insurance co-payments deter mammography use 2Health News:Health insurance co-payments deter mammography use 3Health News:Pennsylvania AFL-CIO Decries Shameful Votes Again by Representatives John Peterson, Joe Pitts and Bill Shuster, Against Children's Health Care 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 2Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 3Health News:New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets 4Health News:Boston Scientific Comments on New England Journal of Medicine Article 2Health News:Boston Scientific Comments on New England Journal of Medicine Article 3Health News:New Therapies Could Change Organ Transplants 2Health News:New Therapies Could Change Organ Transplants 3
    (Date:12/4/2009)... WASHINGTON, Dec. 4 Chemistry World recently highlighted ... Research and Manufacturers of America ( PhRMA ) that ... and related conditions. ,, The report found that ... antivirals. These drugs are either in human clinical trials or ...
    (Date:12/4/2009)... (NYSE Amex: PIP ), a biodefense company ... announced today that the Company is presenting results ... in an inhalation anthrax model in the New ... being presented during an oral session at the ...
    (Date:12/4/2009)... OrthoAccel Technologies, Inc., developers of the AcceleDent ... enhance orthodontics, announced the availability of a new ... , a leader in professional education for many ... focuses on patient views about orthodontic treatment, a ...
    Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4GenVec Announces Third Quarter 2009 Results Conference Call 14630 1GenVec Announces Third Quarter 2009 Results Conference Call 14630 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 1Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 2Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 3Osteotechs MagniFuse 28TM 29 Technology Used in First U S Surgery 5781 4Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 1Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 2Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 3Santaris Pharma A S Expands Executive Team Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA targeted Drug Develop 5776 4